A recent study published in Nature reveals that deactivating a protein called IL-11 can extend the healthy lifespan of mice by nearly 25%. Researchers found that by removing the IL-11 gene or using an anti-IL-11 antibody, the lifespan and health of aging mice dramatically increased. This discovery raises the potential for similar benefits in humans, suggesting that anti-IL-11 treatments could combat age-related diseases with minimal side effects.
The research, conducted by scientists at the Medical Research Council Laboratory of Medical Science and Imperial College London in collaboration with Duke-NUS Medical School, involved administering an anti-IL-11 antibody to aging mice. Results showed a median lifespan extension of 22.5% in males and 25% in females, with treated mice living an average of 155 weeks compared to 120 weeks for untreated mice. Additionally, the treatment reduced cancer-related deaths and various diseases associated with aging, such as fibrosis, chronic inflammation, and poor metabolism.
Lifespan and healthspan are key terms in this study, with lifespan referring to the total number of years an individual lives, and healthspan focusing on the period during which they remain healthy and free from chronic diseases. The study’s co-corresponding author, Professor Stuart Cook, highlighted the link between inhibiting inflammation by blocking IL-11 and extending healthspan and lifetime in mice. These findings suggest that anti-IL-11 treatments could potentially work in humans as well, offering a promising avenue for future clinical trials.
Despite the promising results, caution is advised, as the study was conducted on mice and thus its applicability to humans needs further investigation. Nevertheless, the researchers believe that the study provides valuable insights into the role of IL-11 in the aging process and its potential for extending healthy aging by reducing frailty and physiological signs of aging. Further research is needed to understand the effects of anti-IL-11 treatments in humans and address practical challenges surrounding drug testing and regulatory approval.
While the study’s findings hold significant implications for human health and aging, more research is required to establish the safety and effectiveness of anti-IL-11 treatments in humans. Dr. Richard Siow from King’s College London emphasizes the need for further research to validate the benefits seen in mice in a real-world setting. It is essential to understand the potential risks, benefits, and cost implications associated with extending healthspan and lifespan in humans before implementing such interventions on a larger scale.
In summary, the discovery of the impact of IL-11 inhibition on extending healthy lifespan in mice offers a promising avenue for future research into combating age-related diseases in humans. Despite the need for further investigation and clinical trials, these findings provide valuable insights into the role of IL-11 in aging and the potential benefits of anti-IL-11 treatments. As research progresses, the hope is to extend healthspan and lifespan in humans while improving overall quality of life in later years.
